Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis
DOI:
https://doi.org/10.33448/rsd-v11i11.33963Keywords:
Ozempic; Semaglutide; Obesity; Pharmacology.Abstract
Objective: To analyze the advantages and disadvantages of Ozempic for the treatment of obesity. Methods: Through an integrative analysis, it was possible to highlight different investigations in scientific articles. The article established inclusion criteria, such as keywords, publication language and being on one of the preselected platforms (Scielo, PubMed and RDU) and also established exclusion criteria, such as incomplete research, was the subject investigated and without methods and explicit methods. Results: The Ozempic (semaglutide) has good results in helping to lose weight in obese patients. Despite being developed for the treatment of patients with type 2 diabetes mellitus, the results for obesity were positive. Among the main results is weight loss, which is directly conditioned to the dosage of medication, as well as a better energy intake and a lower preference for fatty foods in the patients' choice. All these factors were considered advantages. Among the disadvantages of using the drug is the fact that it is new in the market, which limits scientific research. According to the authors, some researchers have already established a causal relationship between the use of semaglutide and thyroid cancer in rodents; this factor has not been proven in humans and is considered a disadvantage. Final considerations: The use of Ozempic presents interesting results for weight loss, however, although the long-term side effects of the use of this drug are not known, a factor that may pose a risk to patients who are using Ozempic for it. treatment of obesity.
References
Ades L., Kerbauy R (2002). Obesidade: Realidades e Indagações. Psicologia. USP 13 (1).
Anjos, L. A. (2006) Obesidade e saúde pública. Fiocruz.
Aroda V. R., et al (2018). Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 45(5), 409-418.
Botelho et al. (2011) O Método da Revisão Integrativa nos Estudos Organizacionais. Gestão e Sociedade 5(11), 121-136.
Bray, et al. (2018) The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocrine reviews, 39(2), 79–132.
De Paulo, C. M. et al. (2021) O uso de agonista do receptor GLP-1, semaglutida, como terapia para emagrecimento em pacientes obesos. Brazilian Journal of Surgery and Clinical Research, 35(1) 54-59.
Ercole et al. (2014). Revisão integrativa versus revisão sistemática. Revista Mineira de Enfermagem. 18(1).
Faeh D, et al. (2011) A obesidade, mas não o excesso de peso, está associada a um maior risco de mortalidade. Eur J Epidemiol. 26: 647.
Flegal, K. M., et al. (1998). Overweight and obesity in the United States: Prevalence and trends, 1960-1994. International Journal of Obesity and Related Metabolic Disorders, 22, 39-47.
Gomes, H. K.B.; Trevisan, M. (2021) O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos Com. 29
Guzmán, J.C, & Revelo Enriquez, B. N. (2022). Análisis de costoutilidad de dulaglutida en comparación con semaglutida en el tratamiento de la diabetes mellitus tipo 2 en Colombia. [Trabajo de grado especialización]. Medellín, Colombia. Universidad de Antioquia.
O'Neil P. M. et al (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 25(392), 637-649.
Paccosi S., et al. (2020) Obesity Therapy: How and Why? Curr Med Chem, 27(2):174-186.
Pérez J. P. (2021) Profundizando En La Eficacia, Seguridad Y Eficiencia De Un Nuevo Antidiabético: La Semaglutida Subcutánea SESCAM 23(1).
Peter, R.; Bain, S. C. Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety. 19(7), p.785-798.
Pinheiro A. R. O. et al (2004). Abordagem Epidemiológica da Obesidade. Revista Nutrição, Campinas, 17(4):523-533.
Phillips A., Clements J. N. J. (2022) Clinical review of subcutaneous semaglutide for obesity. Clin Pharm Ther. 47(2):184-193.
Smits, M. M.; Van, R. D. l. (2021) Safety of semaglutide. Frontiers in Endocrinology, 12.
Tarozo M, et al. (2020) Impacto das Consequências Psicossociais do Estigma do Peso no Tratamento da Obesidade: uma Revisão Integrativa da Literatura. Psicologia, Ciência e Profissão. 40.
Wanderley EN, Ferreira VA (2010). Obesidade: uma perspectiva plural. Ciência & Saúde Coletiva, 15(1), 185-194.
Wilding, J. et al. (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal Of Medicine, 389 (11), 989-1002
World Health Organization (1998). Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Hanna Benayon Oliveira Sabbá; Caio Antônio Silva Viana; Caroline Baía Silva; Diogo Ramos Alves; Jhon Lennon Ferreira Miranda; Manuella Carneiro Rodruigues; Pedro Henrique Farias dos Santos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
